Coura et al., reported in their cohort of 38 AOTs, no statistically significant association between the presence of mutations (mainly KRAS G12V and G12R) and clinicopathological parameters (including patient's age, tumor size, location, follicular or extrafollicular variants, and fibrous capsule thickness) [22]. The gene discussed is KRAS; the disease is neoplasm.